ABSTRACT: Background and purpose: N-arachidonoyl dopamine (NADA) has complex effects on nociception mediated via cannabinoid CB1 receptors and the transient receptor potential vanilloid receptor 1 (TRPV1). Anandamide, the prototypic CB1/TRPV1 agonist, also inhibits T-type voltage-gated calcium channel currents (ICa). These channels are expressed by many excitable cells, ... Continue Reading